Covalon Technologies, an advanced medical technologies company, has entered additional markets in the Middle East, including Qatar, Iran and United Arab Emirates with its infection management and advanced wound care products.
The company’s flagship advanced wound care product ColActive Plus Ag has been trialled successfully over the past several months in the eight hospital system managed by Hamad Medical Corporation, the main provider of secondary and tertiary healthcare in Qatar and one of the leading hospital providers in the Middle East.
The company has entered into a distribution agreement to make Covalon’s entire product line available for distribution to the Ministry of Health and private hospital systems in Iran.
It has also commenced the process of registering its full product line with SEHA Abu Dhabi Health Services Company, who owns and operates 12 hospitals, 62 ambulatory and primary healthcare centers, and two blood banks, across the entire United Arab Emirates.
It expects to immediately introduce its IV Clear, SurgiClear and CovaWound product lines to Hamad Medical Corporation’s five specialist hospitals and three community hospitals in Qatar.
Brian Pedlar, chief executive officer (CEO) of Covalon, said: “Our success in Saudi Arabia has opened the doors for Covalon to capture market share in other important countries in the Middle East.
“These additional markets have the opportunity to significantly increase our business in the region.”
Hamed Abbasian, vice president of business development at Covalon, said: “ColActive Plus Ag has been used successfully in Iran since 2011 in the treatment of many extremely hard to heal chronic wounds and is considered as one of the most efficacious dressings for the treatment of chronic wounds by the Professional Society of Wound Healing of Iran.
“We have entered into a distribution agreement to expand the distribution of our ColActive Plus Ag product and to provide Covalon’s IV Clear, SurgiClear, and CovaWound product lines in Iran for the first time.
“With key opinion leaders like Dr Massoud Ghasemi, a renowned intervention cardiologist in Iran, supporting the launch of our infection management and wound care products into the market, we see the opportunity for all of Covalon’s products to be category leaders in the Iranian healthcare market.”
Covalon, Risk management, Healthcare, MENA, Canada